Efficacy of topotecan in pretreated metastatic poorly differentiated extrapulmonary neuroendocrine carcinoma

Therapeutic options for metastatic poorly differentiated neuroendocrine carcinoma (NEC) after prior platinum‐based chemotherapy are limited. Topotecan is an approved second‐line chemotherapy for small cell lung cancer (SCLC). NEC is often considered to show a biological behavior similar to SCLC. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Apostolidis, Leonidas, Bergmann, Frank, Jäger, Dirk, Winkler, Eva Caroline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055186/
https://www.ncbi.nlm.nih.gov/pubmed/27456539
http://dx.doi.org/10.1002/cam4.807

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055186/
https://www.ncbi.nlm.nih.gov/pubmed/27456539
http://dx.doi.org/10.1002/cam4.807

Ejemplares similares